-
公开(公告)号：US20120214762A1
公开(公告)日：2012-08-23
申请号：US13420988
申请日：2012-03-15
IPC分类号： A61K31/506 , A61P37/06 , A61P11/00 , A61P25/00 , A61P1/00 , A61P19/02 , A61P29/00 , A61P17/06 , A61P15/00 , A61P35/00 , C07D417/14 , C07D413/14 , C07D403/04 , A61K31/5377 , C07D405/14 , C07D401/14 , A61K31/53 , C07D403/14 , C07F7/10 , A61K31/695 , C07D491/107 , C07D491/08 , C07D487/04 , A61P11/06
CPC分类号： C07F7/0805 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D491/08 , C07D491/10 , C07D491/107
摘要： The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
摘要翻译： 本发明涉及式I的新化合物：其中A，Y，R 1，R 2和下标b各自具有本文所述的含义，式I化合物和立体异构体，几何异构体，互变异构体，溶剂合物，代谢物，同位素，药学上 其可接受的盐或前药。 式I化合物及其药物组合物可用于治疗观察到NF-kB信号传导的不期望或过度活化的疾病和病症。
-
公开(公告)号：US08901313B2
公开(公告)日：2014-12-02
申请号：US13420988
申请日：2012-03-15
IPC分类号： C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04 , A61K31/506 , A61K31/53 , A61K31/4184 , A61P19/02 , C07D403/14 , C07D491/10
CPC分类号： C07F7/0805 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D491/08 , C07D491/10 , C07D491/107
摘要： The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
摘要翻译： 本发明涉及式I的新化合物：其中A，Y，R 1，R 2和下标b各自具有本文所述的含义，式I化合物和立体异构体，几何异构体，互变异构体，溶剂合物，代谢物，同位素，药学上 其可接受的盐或前药。 式I化合物及其药物组合物可用于治疗观察到NF-kB信号传导的不期望或过度活化的疾病和病症。
-
公开(公告)号：US07449337B2
公开(公告)日：2008-11-11
申请号：US11626759
申请日：2007-01-24
申请人： Chiranjit Deka , Jianwen Feng
发明人： Chiranjit Deka , Jianwen Feng
CPC分类号： G01N33/5094 , G01N2015/0069 , Y10T436/10 , Y10T436/101666 , Y10T436/107497 , Y10T436/108331 , Y10T436/25 , Y10T436/25125
摘要： A lytic reagent composition and methods for differential analysis of leukocytes are disclosed. In embodiments, the analysis may utilize optical measurements in flow cytometry based hematology analyzers. The reagent system includes an anionic surfactant in a hypotonic solution, an inorganic buffer to maintain the pH in a range from about 6 to about 10, and optionally a leukocyte stabilizer. The reagent system is used to lyse red blood cells and stabilize the leukocytes to enable multi-part differentiation of leukocytes in a near physiologic pH environment on a flow cytometry based hematology analyzer using axial light loss, light scatter intensity, high-numerical aperture side scatter, and time-of-flight measurements.
摘要翻译： 公开了一种裂解试剂组合物和白细胞差异分析方法。 在实施方案中，分析可以利用基于流式细胞仪的血液分析仪中的光学测量。 试剂系统包括在低渗溶液中的阴离子表面活性剂，将pH保持在约6至约10范围内的无机缓冲剂和任选的白细胞稳定剂。 试剂系统用于裂解红血细胞并稳定白细胞，使得在基于流式细胞仪的血液分析仪上，在近生理pH环境中白细胞多部分分化，使用轴向光损失，光散射强度，高数值孔径侧散射 和飞行时间测量。
-
公开(公告)号：US20080176331A1
公开(公告)日：2008-07-24
申请号：US11626759
申请日：2007-01-24
申请人： Chiranjit Deka , Jianwen Feng
发明人： Chiranjit Deka , Jianwen Feng
IPC分类号： G01N33/48
CPC分类号： G01N33/5094 , G01N2015/0069 , Y10T436/10 , Y10T436/101666 , Y10T436/107497 , Y10T436/108331 , Y10T436/25 , Y10T436/25125
摘要： A lytic reagent composition and methods for differential analysis of leukocytes are disclosed. In embodiments, the analysis may utilize optical measurements in flow cytometry based hematology analyzers. The reagent system includes an anionic surfactant in a hypotonic solution, an inorganic buffer to maintain the pH in a range from about 6 to about 10, and optionally a leukocyte stabilizer. The reagent system is used to lyse red blood cells and stabilize the leukocytes to enable multi-part differentiation of leukocytes in a near physiologic pH environment on a flow cytometry based hematology analyzer using axial light loss, light scatter intensity, high-numerical aperture side scatter, and time-of-flight measurements.
摘要翻译： 公开了一种裂解试剂组合物和白细胞差异分析方法。 在实施方案中，分析可以利用基于流式细胞仪的血液分析仪中的光学测量。 试剂系统包括在低渗溶液中的阴离子表面活性剂，将pH保持在约6至约10范围内的无机缓冲剂和任选的白细胞稳定剂。 试剂系统用于裂解红血细胞并稳定白细胞，使得在基于流式细胞仪的血液分析仪上，在近生理pH环境中白细胞多部分分化，使用轴向光损失，光散射强度，高数值孔径侧散射 和飞行时间测量。
-
-
-
搜索结果
4 条记录 (耗时 0.031 秒)
